Analysis of a publicly available data (TCGA PRAAD cohort) from a cohort of 422 PCa patients revealed that high CXCL12 expression is associated with a significantly higher rate of biochemical tumor recurrence (Fig. 3C). Here, CXCL12 is linked to neoplasm.